DBV Technologies S.A. (NASDAQ:DBVT) Analyst Ratings as of Jun 27, 2018

June 27, 2018 - By Rebecca Betts

DBV Technologies S.A. (NASDAQ:DBVT) Corporate Logo

DBV Technologies S.A. (NASDAQ:DBVT) Ratings Coverage

In total 3 analysts cover DBV Technologies SA – American (NASDAQ:DBVT). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 3 are the (NASDAQ:DBVT)’s analyst reports since February 14, 2018 according to StockzIntelligence Inc. On Tuesday, March 27 Deutsche Bank maintained DBV Technologies S.A. (NASDAQ:DBVT) with “Buy” rating. On Thursday, March 15 the rating was maintained by H.C. Wainwright with “Buy”. Listed here are DBV Technologies S.A. (NASDAQ:DBVT) PTs and latest ratings.

27/03/2018 Broker: Deutsche Bank Rating: Buy New Target: $33.0000 Maintain
15/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $50.0 Maintain
14/02/2018 Broker: Citigroup Rating: Buy New Target: $57.0

Ticker’s shares touched $19.53 during the last trading session after 0.71% change.DBV Technologies S.A. has volume of 37,198 shares. Since June 27, 2017 DBVT has declined 29.21% and is downtrending. The stock underperformed the S&P500 by 41.78%.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.The firm is valued at $1.16 billion. The Company’s lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.Last it reported negative earnings. The firm is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cowÂ’s milk protein allergy and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of henÂ’s egg allergy; and booster vaccine for Bordatella pertussis.

More recent DBV Technologies S.A. (NASDAQ:DBVT) news were announced by Seekingalpha.com, Nasdaq.com and Nasdaq.com. The first one has “Aimmune Therapeutics: Special Situation Biotech Opportunity” as a title and was announced on June 08, 2018. The next is “DBV Technologies: Ordinary and Extraordinary General Meeting of June 22, 2018 – Procedures for Obtaining …” on June 01, 2018. And last was announced on June 04, 2018, called “Investor Expectations to Drive Momentum within Momo, Barrick Gold, Grupo Financiero Santander Mexico SAB de CV …”.

DBV Technologies S.A. (NASDAQ:DBVT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.